|
Research
in this laboratory focuses on two fundamental problems in gene
regulation and stem cell biology. The first deals with the
molecular mechanisms responsible for regulating gene regulatory
networks that control the self-renewal of stem cells. The second deals with
molecular mechanisms that control the selective binding of
transcription factors to gene regulatory sequences. Details for each project
are discussed below to help explain the long-term goals of this
laboratory.
Understanding
gene regulatory networks that coordinate the transcription of sets
of genes during cell growth and differentiation is one of the
biggest challenges facing biomedical scientists. Deciphering the
mechanisms that control gene regulatory networks at the molecular
level will not only enable us to better understand normal
physiology, it will also provide critical insights into aberrant
gene regulation in diseases, such as cancer. Although substantial
progress has been made in understanding the mechanisms used to
regulate individual genes, relatively little is known about the
molecular mechanisms used to regulate the transcription of sets of
genes (coordinate gene regulation). A major goal of the work in
this laboratory is to understand the fundamental mechanisms and
signaling pathways that orchestrate the early stages of
mammalian embryogenesis and control the self-renewal and pluripotency
of embryonic stem (ES) cells. Currently, our studies focus
on the molecular mechanisms that control the self-renewal of stem
cells, because this problem is central to our understanding of
developmental biology, regenerative medicine and cancer biology.
In the case of cancer, learning how to disrupt the self-renewal of
cancer stem cells holds the key to more effective cures in cancer.
To better understand the self-renewal of stem cells, we are
studying a gene regulatory network used to coordinately control
the transcription of genes that play key roles in the self-renewal
of ES cells. As part of these studies, we are are examining how ES cells coordinately control the transcription of six of their
genes (FGF-4, UTF1, Sox2, Oct-3/4, Fbx-15, and Nanog) that are
regulated by the cooperative and synergistic action of the
transcription
factors Sox2 and Oct-3/4 (also known as Oct4). For each of these
genes, Sox2 and Oct-3/4 binds cooperatively to two closely-spaced
DNA regulatory elements that exert powerful effects on the
promoters of each of the six genes (Figure 1) Disruption of
the two DNA regulatory elements in each gene leads to a dramatic
decrease (>90%) in the activity of each gene’s promoter. ES cells are employed in our studies, because they serve as
excellent model systems for early mammalian development and
because differentiation of these cells suppresses their ability to
form tumors. Thus, this model system provides an excellent
opportunity to study the molecular mechanisms by which
differentiation blocks the malignant properties of tumor cells.
For our studies, a wide range of approaches are employed,
including: gene cloning, gene targeting, DNA arrays, construction
of promoter/reporter gene constructs, PCR, site-directed
mutagenesis, gel mobility shift analysis, in vitro footprint
analysis, western, northern and Southern blot analyses, in vitro
transcription/translation, and chromatin immunoprecipitation
(ChIP).
Recent and Current
Work:
Several studies
have identified large sets of genes in embryonic stem (ES) cells that are associated with the
transcription factors Sox2 and Oct-3/4. Other studies have
shown that Sox2 and Oct-3/4 work together as master regulators to
cooperatively stimulate the transcription of their own genes as
well as a larger network of genes required for
embryogenesis. Moreover, small changes in the levels of
Sox2:Oct-3/4 target genes, such as Oct-3/4 and Sox2, alter the fate of stem
cells. Although positive feedforward and feedback
loops have been proposed to explain the activation of these genes,
relatively little is known about the mechanisms that prevent their overexpression. Our studies have shown that elevating
Sox2 levels initiates a negative feedback loop, which
reduces the endogenous expression of at least five Sox2:Oct-3/4
target genes in EC cells and ES cells (Boer et al. Nucleic Acids
Research, 35: 1773-1786, 2007). Moreover, these studies have
shown the ability of Sox2 to limit transcription is
dependent on the binding sites for Sox2 and Oct-3/4. In
addition, this effect of Sox2 is dependent on its transactivation
domain, which is located at its C-terminus.
These studies led to the prediction that elevating the levels of
Sox2 in ES cells would induce their differentiation. To test
this hypothesis, we engineered mouse ES cells for inducible
overexpression of Sox2. Using this model system, we have
recently shown that a small increase in the level of Sox2 (2-fold
or less) rapidly triggers the differentiation of ES cell (Kopp et
al., Stem Cells, 26:903-911, 2008). Together, these studies provide
new insights into the diversity of mechanisms that control
Sox2:Oct-3/4 target genes. Importantly, our studies argue
that Sox2 functions as a molecular rheostat for the control of a
key transcriptional regulatory network that orchestrates mammalian
embryogenesis as well as the self-renewal and pluripotency of ES
cells. As part of our ongoing studies, we are testing our
hypothesis that nature uses a squelching mechanism, as part of a
negative feedback loop, to help maintain the proper expression of
Sox2:Oct-3/4 target genes during development. We are also
examining whether genes activated rapidly by Sox2 overexpression
play an critical role in the induction of ES cell differentiation.
Research
in this laboratory also focuses on transcription factors that
belong to the Ets superfamily. Our current efforts seek to
understand how Ets proteins regulate genes that play key roles in
cancer. For these studies, we are focusing on the Ets proteins,
Ets1, Ets2 and Elf3, and a target gene of Ets proteins, the type II TGF-β-receptor gene
(Kim et al., JBC 277:17520-17530, 2002; Kopp et al., JBC
279:19407-19420, 2004). The type II TGF-β-receptor gene is of
interest, because it mediates the effects of the multi-functional
factor TGF-β, which exerts both positive and negative effects on
tumor growth and metastasis in many cancers. Ets proteins
are of interest because Ets proteins are overexpressed in many
cancers. Several years ago, our laboratory demonstrated that Elf3, like seven other Ets
proteins, contain an autoinhibitory domain, which
regulates its binding to DNA. To better understand the molecular
mechanisms by which Elf3 regulates these processes, we created a
large series of Elf3 mutant proteins with specific domains deleted
or targeted by point mutations. The modified forms of Elf3
were used to analyze the contribution of each domain to DNA
binding and the activation of gene expression. Our work
demonstrates that three regions of Elf3, in addition to its DNA
binding domain (ETS domain), influence Elf3 binding to DNA,
including its transactivation domain, which behaves as an
autoinhibitory domain. Importantly, disruption of the transactivation domain relieves the autoinhibition of Elf3 and
enhances Elf3 binding to DNA (Kopp
et al. JBC 282:3027-3041, 2007). Moreover, we have
shown that the N-terminal region of Elf3,
which contains the transactivation domain, interacts with its
C-terminus, which contains the ETS domain. Equally
important, we have shown that the interaction between the two
domains of Elf3 is disrupted when the transactivation domain of
Elf3 interacts with the co-activator Med 23. Other work in
this laboratory indicates that this unexpected role of
transactivation domains is not limited to Ets proteins. We
have shown that the transactivation domain of
the
transcription factors Sox11 behaves as an autoinhibitory domain (Wiebe et al., JBC
278:17901-17911, 2003). Together, our studies lead to
a new paradigm for gene activation and the mechanisms by which
transcription factors are selectively recruited to the correct set
of genes in a given cell type. More specifically, our
findings suggest a model in which the binding of some, if not
most, transcription factors to DNA is mediated by first
interacting with an appropriate co-activator that converts them
from an autoinhibited form to a DNA binding form. Currently, it is commonly argued that, after
transcription factors bind to DNA, they recruit co-activators to
the gene. Our model posits that transcription factors, such
as Ets proteins, must
interact with appropriate co-activators in order to bind to
DNA. Accordingly, our model predicts that co-activators play
a key role in determining which sets of genes are activated by
transcription factors whose transactivation domains function as
autoinhibitory domains. |